Healthmonix Advisor

Are you ready to jump back into the MIPS program?   

The Centers for Medicare & Medicaid Services (CMS) have released Final Performance Feedback for the 2022 Merit-based Incentive Payment System (MIPS) performance period. We are seeing record maximum incentives of 8.25% for providers who achieved top scores.   

In the 2024 Proposed PFS Rule released in July 2023, CMS outlined a new option for MSSP participants to report quality measures called the Medicare CQM option. CMS created this reporting option to address concerns raised by ACOs and others, while still transitioning ACOs toward digital quality measure reporting. 

Read on to learn more about the new proposed option for MSSP participants. 

With 2022 MIPS preliminary scores available, oncology practices are increasingly seeing how the Cost category negatively affects their overall MIPS scores.  

Before CMS added the Cost category to 2022 MIPS scores, research hinted that oncology and other specialties with higher healthcare costs might face more adverse effects than other specialties. Numerous oncology practices opted for an Extreme and Uncontrollable Circumstances (EUC) exemption for the Cost category in 2022, mitigating the impact of cost measures on them.  

Read on to learn more about how MIPS Cost scores are affecting Oncology practices.

Discover the game-changing impact of the 2022 MIPS Final Score Preview period as we delve into the long-awaited return of Cost category scores after 3 years. The implications for providers' total MIPS scores are profound, and we have the insights you need to navigate this transformative shift.

Last week, CMS confirmed that 2022 MIPS scores for eligible providers will include the Cost performance category. Per CMS: 

“For the 2020 and 2021 performance periods, CMS reweighted the MIPS Cost performance category to 0% as a result of the COVID-19 public health emergency (PHE). For the 2022 performance period/2024 MIPS payment year (hereafter written as “2022 performance period”), CMS conducted an empirical analysis to assess whether any or all cost measures were continually impacted by the COVID-19 PHE and, if so, whether it would be appropriate for CMS to reweight the Cost performance category again under § 414.1380(c)(2) or to exclude any individual cost measures.  

Read on to learn more about how these changes may affect your MIPS participation and payment year.

In today's evolving healthcare landscape, accurate and efficient reporting is crucial for billing companies. However, the burden of Merit-based Incentive Payment System (MIPS) reporting can be overwhelming. 

That's where Healthmonix comes in. As a leading MIPS Reporting Registry, we specialize in partnering with billing companies to streamline and optimize their clients’ MIPS reporting. 

Let’s explore the numerous benefits of using a MIPS Reporting Registry like Healthmonix. Discover how our partnership can revolutionize billing operations, simplify MIPS reporting, and unlock new opportunities for success.